{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"AndroMETa-CRC","nct_id":"NCT07525206","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=andrometa-crc-nct07525206. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"AndroMETa-CRC","arms":[{"description":"Participants will receive telisotuzumab adizutecan + Bevacizumab as part of an approximately 36 months study duration.","label":"Ph 3: Telisotuzumab Adizutecan + Bevacizumab","type":"EXPERIMENTAL"},{"description":"Participants will receive standard of care (SOC) trifluridine and tipiracil +Bevacizumab as part of an an approximately 36 months study duration.","label":"Ph 3: SOC Trifluridine and Tipiracil + Bevacizumab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-03","type":"ESTIMATED"},"conditions":["Colorectal Cancer"],"enrollment":{"count":990,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Telisotuzumab adizutecan","otherNames":[],"type":"DRUG"},{"name":"Bevacizumab","otherNames":[],"type":"DRUG"},{"name":"Trifluridine/Tipiracil","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-19","lead_sponsor":"AbbVie","official_title":"An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With Refractory Metastatic Colorectal Cancer","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase 3: Objective Response (OR) as assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to Approximately 15 Months"},{"measure":"Phase 3: Overall Survival (OS)","timeFrame":"Up to Approximately 36 Months"}],"references":[],"start_date":{"date":"2026-05-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer","url":"https://clinicaltrials.gov/study/NCT07525206"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/andrometa-crc-nct07525206"}